Rockefeller Capital Management L.P. Has $47.17 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Rockefeller Capital Management L.P. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,630,089 shares of the biopharmaceutical company’s stock after buying an additional 32,524 shares during the period. Rockefeller Capital Management L.P.’s holdings in Pfizer were worth $47,169,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of PFE. Northwest & Ethical Investments L.P. lifted its holdings in shares of Pfizer by 3.0% during the 3rd quarter. Northwest & Ethical Investments L.P. now owns 263,531 shares of the biopharmaceutical company’s stock worth $7,627,000 after acquiring an additional 7,799 shares during the period. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer during the third quarter valued at approximately $35,000. Vinva Investment Management Ltd lifted its stake in Pfizer by 312.5% during the third quarter. Vinva Investment Management Ltd now owns 193,465 shares of the biopharmaceutical company’s stock worth $5,628,000 after purchasing an additional 146,564 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its stake in Pfizer by 107.9% in the third quarter. Public Sector Pension Investment Board now owns 1,705,865 shares of the biopharmaceutical company’s stock valued at $49,368,000 after buying an additional 885,500 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.5 %

Shares of NYSE:PFE opened at $26.21 on Friday. The company has a market capitalization of $148.53 billion, a price-to-earnings ratio of 35.42, a P/E/G ratio of 0.70 and a beta of 0.67. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The business’s 50-day moving average is $27.83 and its 200-day moving average is $28.49. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.17) EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.41%. Pfizer’s payout ratio is currently 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Citigroup started coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.